Douglas Miehm
Stock Analyst at RBC Capital
(3.98)
# 1,788
Out of 4,988 analysts
409
Total ratings
51.1%
Success rate
5.5%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $43.00 | $33.25 | +29.32% | 3 | Aug 12, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $21.00 | $17.26 | +21.67% | 42 | Aug 10, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $345 | $283.49 | +21.70% | 21 | Aug 9, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Hold | $15 → $16 | $16.90 | -5.33% | 44 | Aug 7, 2026 | |
| TSX: DR Medical Facilities Corporation | Reiterated: Hold | $19.00 | $15.02 | +26.50% | 47 | Aug 7, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Reiterated: Buy | $9.50 → $11.00 | $10.25 | +7.32% | 28 | Aug 7, 2026 | |
| MNKD MannKind | Reiterated: Hold | $4.75 | $3.54 | +34.18% | 10 | Aug 6, 2026 | |
| PCRX Pacira BioSciences | Reiterated: Hold | $24 → $25 | $24.69 | +1.26% | 6 | Aug 5, 2026 | |
| BLCO Bausch + Lomb | Reiterated: Buy | $21 | $16.85 | +24.63% | 38 | Jul 30, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Reiterated: Hold | $12.60 | $7.92 | +59.06% | 104 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.00 | $4.24 | +65.09% | 22 | May 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.93 | $16.56 | -52.11% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.5 → $3.5 | $0.77 | +354.55% | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $3.99 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 | €91.00 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $7.98 | n/a | 6 | Aug 4, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.000001 | n/a | 2 | Nov 6, 2013 |
Apotex Health Corp.
Aug 12, 2026
Reiterated: Buy
Price Target: $43.00
Current: $33.25
Upside: +29.32%
DRI Healthcare Trust
Aug 10, 2026
Reiterated: Buy
Price Target: $21.00
Current: $17.26
Upside: +21.67%
Ligand Pharmaceuticals
Aug 9, 2026
Reiterated: Buy
Price Target: $345
Current: $283.49
Upside: +21.70%
Aurinia Pharmaceuticals
Aug 7, 2026
Reiterated: Hold
Price Target: $15 → $16
Current: $16.90
Upside: -5.33%
Medical Facilities Corporation
Aug 7, 2026
Reiterated: Hold
Price Target: $19.00
Current: $15.02
Upside: +26.50%
Knight Therapeutics Inc.
Aug 7, 2026
Reiterated: Buy
Price Target: $9.50 → $11.00
Current: $10.25
Upside: +7.32%
MannKind
Aug 6, 2026
Reiterated: Hold
Price Target: $4.75
Current: $3.54
Upside: +34.18%
Pacira BioSciences
Aug 5, 2026
Reiterated: Hold
Price Target: $24 → $25
Current: $24.69
Upside: +1.26%
Bausch + Lomb
Jul 30, 2026
Reiterated: Buy
Price Target: $21
Current: $16.85
Upside: +24.63%
Bausch Health Companies Inc.
Jul 30, 2026
Reiterated: Hold
Price Target: $12.60
Current: $7.92
Upside: +59.06%
May 10, 2026
Reiterated: Buy
Price Target: $7.00
Current: $4.24
Upside: +65.09%
Mar 19, 2026
Reiterated: Buy
Price Target: $7.93
Current: $16.56
Upside: -52.11%
Nov 19, 2025
Reiterated: Buy
Price Target: $2.5 → $3.5
Current: $0.77
Upside: +354.55%
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $3.99
Upside: n/a
Jun 23, 2021
Reiterated: Buy
Price Target: €22.00
Current: €91.00
Upside: n/a
Aug 4, 2016
Reiterated: Hold
Price Target: $1
Current: $7.98
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.000001
Upside: n/a